Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07817082) titled 'Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer' on Sept. 8.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital

Condition: Advanced Breast Cancer With Ultra-Low HER2 Expression

Intervention: Drug: SHR- A1811

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: September 1, 2026

Target Sample Size: 30

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/stu...